Company Updates - The company presented data on Bcl-2 inhibitor APG-2575 (lisaftoclax) in combination with azacitidine for myeloid malignancies at the 2025 ASCO annual meeting, along with updates on MDM2-p53 inhibitor APG-115 (alrizomadlin) for advanced adenoid cystic carcinoma (ACC) and other solid tumors [1][2] Clinical Data Highlights - APG-2575 demonstrated promising results in a global multicenter Ib/II study for relapsed/refractory acute myeloid leukemia (R/R AML) with an overall response rate (ORR) of 43.2% among 44 evaluable patients, including a complete response (CR) or complete response with incomplete blood count recovery (CRi) rate of 31.8% [1] - In a subgroup of 22 patients previously treated with venetoclax, the ORR was 31.8%, with 22.8% achieving CR/CRi [1] - For newly diagnosed myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), APG-2575 showed an ORR of 80% in 15 evaluable patients, with 40% achieving CR [2] - Among 22 evaluable R/R MDS/CMML patients, the ORR was 50%, with 27.3% achieving CR [2] - APG-115 showed anti-tumor activity with an ORR of 16.7% in advanced ACC patients and 100% disease control rate (DCR) in a cohort of cholangiocarcinoma patients [2] Financial Forecast and Valuation - The company maintains its net loss forecast for 2025 and 2026 at 1.095 billion and 319 million respectively [3] - Due to the promising data from APG-2575, the company sees potential for unlocking more commercial value in AML/MDS indications and has raised its target price by 25.5% to HKD 69, indicating a 16.2% upside from the current stock price [3]
亚盛医药-B(06855.HK)：2025ASCO读出APG-2575亮眼AML/MDS数据